19:57 , Apr 27, 2018 |  BC Week In Review  |  Clinical News

FDA places clinical hold on Ph I of Epizyme's tazemetostat

Epizyme Inc. (NASDAQ:EPZM) said FDA placed a partial clinical hold on tazemetostat (E7438, EPZ-6438) following a report of a patient who developed secondary T cell lymphoma during a Phase I pediatric trial of the selective...
21:14 , Jan 23, 2018 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Solid tumors Cell culture and mouse studies suggest combining Votrient pazopanib and a potassium channel inhibitor could help treat rhabdoid tumors. High throughput screening of a library of approved drugs in six human rhabdoid...
19:54 , Nov 6, 2017 |  BC Innovations  |  Distillery Techniques

Biomarkers

TECHNOLOGY: Tissue markers Tumor levels of SMARCA2 RNA could help predict responses to EZH2 inhibitors in cancers harboring mutations in the SWI/SNF complex. In 20 human ovarian, lung, gastrointestinal and other cancer cell lines with...
19:58 , Sep 21, 2017 |  BC Innovations  |  Tools & Techniques

On your marks

With less fanfare than the first two waves, a quiet rise in activity is driving a revival of interest in epigenetics, despite little progress in solving the fundamental challenges that have dogged the field from...
22:43 , Jun 14, 2017 |  BC Extra  |  Clinical News

Epizyme gains on latest tazemetostat readout in NHL

Epizyme Inc. (NASDAQ:EPZM) gained $1.20 (11%) to $12.35 on Wednesday as investors digested updated results from a Phase II trial of tazemetostat (EPZ-6438) in patients with relapsed or refractory diffuse large B cell lymphoma (DLBCL)...
20:58 , Jun 1, 2017 |  BC Week In Review  |  Clinical News

Epizyme reports interim Phase II data for tazemetostat in sarcomas

In an abstract released ahead of the American Society of Clinical Oncology meeting in Chicago, Epizyme Inc. (NASDAQ:EPZM) reported interim data from a cohort of 31 evaluable patients with SWI/SNF related matrix associated actin dependent...
07:00 , Jul 25, 2016 |  BC Week In Review  |  Clinical News

Tazemetostat: Preliminary Phase I/II data

Preliminary data from 47 evaluable relapsed or refractory NHL patients in the Phase II portion of an open-label, international Phase I/II trial showed that twice-daily 800 mg oral tazemetostat led to an ORR of 27.7%,...
08:00 , Jan 25, 2016 |  BC Week In Review  |  Clinical News

Tazemetostat: Phase II started

Epizyme began an open-label, international Phase II trial to evaluate 800 mg oral tazemetostat twice daily in about 90 adult patients. The first cohort will comprise patients with malignant rhabdoid tumor, rhabdoid tumor of the...
08:00 , Jan 25, 2016 |  BC Week In Review  |  Clinical News

Tazemetostat: Phase I started

Epizyme began an open-label, international Phase I trial of oral tazemetostat in 28-day cycles in about 44 pediatric patients. The dose-escalation part will evaluate twice-daily doses of 240, 300, 400 and 520 mg/m 2 tazemetostat...
07:00 , Sep 24, 2015 |  BC Innovations  |  Distillery Techniques

Techniques: Low expression levels of SWI/SNF related matrix associated actin dependent regulator of chromatin subfamily a member 4 (SMARCA4; BRG1) and SMARCB1 (

Biomarkers SMARCA4 SMARCB1 SWI/SNF related matrix associated actin dependent regulator of chromatin subfamily a member 4 BRG1 SNF5 INI1 The Netherlands Cancer Institute...